The results of this study demonstrated that ISL could reverse TGF-β-induced endometrial cancer cell migration through inhibition of TGF-β/Smad signaling pathway with subsequent increased E-cadherin expression and reduced N-cadherin, vimentin, α-SMA, p-Smad3, and TWIST1/2 expression (Figure 9). The gene discussed is TWIST1; the disease is endometrial cancer.